書籍詳細

1. 糖尿病におけるインスリン抵抗性と薬物療法

P.32 掲載の参考文献

• 1) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
  pubmed

• 2) Fujita T et al:Regulation of insulin resistance in obese and/or diabetec animals by 3 [-1- (methlcyclohexylmethoxy) benzi]- thiazolidine-2, 4 dione (ADO-3870, U-63287, ciglitazone), a new antidiabatic agent. Diabetes 32:804-810, 1983

• 3) Fujiwara T et al:Characterization of new oral antidiabetic agent CS-045:studiws in KK and ob/ob mice and Zucker fatty rats. Diabetes 37:1549-1558, 1988
  pubmed

• 4) Iwamoto Y et al:Effect of new oral antidiabetic agent CS-045 on glucose tolerance and insulin secretion in patients with NIDDM. Diabetes Care 14:1083-1086, 1991
  pubmed

• 5) 小坂樹徳ほか:新しい経口血糖降下薬CS-045のインスリン非依存糖尿病患者に対する単独投与における臨床評価-プラセポを対照薬とした二重盲検比較試験-. 臨床医薬 9(Suppl 3):61-93, 1993

• 6) Kahn CR:Banting Lecture. Insulin action, diabetogenes, and the cause of type II diabetes. Diabetes 43(8):1066-1084, 1994
  pubmed

• 7) DeFronzo RA:Lilly Lecture. The triumvirate:beta-cell, muscle, liver. A collusion responsible for NIDDM. Diabetes 37:667-687, 1987
  pubmed

• 8) Ryysy L et al:Hepatic fat content and insulin action on free fatty acids and glucose metabolism rather than insulin absorption are associated with insulin requirements during insulin therapy in type 2 diabetic patients. Diabetes 49:749-758.
  pubmed

• 9) Krssak M et al:Intramyocellular lipid concentrations are correlated with insulin sensitivity in humans:a 1H NMR spectroscopy study. Diabetologia 42:113-116, 1999
  pubmed

• 10) Lawrence RD:Lipodystrophy and hepatomegaly with diabetes, lipaemia, and other metabolic disturbances:a case throwing new light on the action of insulin. Lancet 1:724-731, 773, 1946

• 11) Tontonoz P et al:Adipocyte-specific transcription factor ARF6 is a heterodimeric complex of two nuclear hormone receptors, PPAR gamma and RXR alpha. Nucleic Acids Res 22(25):5628-5634, 1994
  pubmed

• 12) Oishi Yet al:Kruppel-like transcription factor KLF5 is a key regulator of adipocyte differentiation. Cell Metabolism 1:27-39, 2005

• 13) Okuno A et al:Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101(6):1354-1361, 1998
  pubmed

• 14) Yamauchi T et al:The mechanisms by which both heterozygous peroxisome proliferator-activated receptor γ(PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 276(44):41245-41254, 2001

• 15) Kubota N et al:PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4(4):597-609, 1999
  pubmed

• 16) Deeb SS et al:A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 20(3):284-287, 1998
  pubmed

• 17) Hara K et al:The Pro12Ala polymorphism in PPAR gamma2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271(1):212-216, 2000
  pubmed

• 18) Xu H et al:Chronic inflammation in fat plays a crucial role in the development of obesity-related insulin resistance. J Clin Invest 112:1821-1830, 2003

• 19) Stuart P et al:Obesity is associated with macrophage accumulation in adipose tissue. J Clin Invest 112:1796-1808, 2003

• 20) Gavrilova A et al:Surgical implantation of adipose tissue reverses diabetes in lipoatrophic mice. J Clin Invest 105:271-278, 2000

• 21) Shimomura I et al:Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76, 1999
  pubmed

• 22) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7(8):941-946, 2001
  pubmed

• 23) Scherer PE et al:A novel serum protein similar to Clq, produced exclusively in adipocytes. J Biol Chem 270(45):26746-26749, 1995

• 24) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun. 221(2):286-289, 1996
  pubmed

• 25) Hu E et al:AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271(18):10697-10703, 1996

• 26) Nakano Y et al:Isolation and characterization of GBP28, a novel gelatin-binding protein purified from human plasma. J Biochem (Tokyo). 120(4):803-812, 1996
  pubmed

• 27) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8(11):1288-1295, 2002
  pubmed

• 28) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423(6941):762-769, 2003
  pubmed

• 29) Hotta K. et al:Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
  pubmed

• 30) Ouchi N et al:Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057, 2001

• 31) Ouchi N et al:Novel modulator for endothelial adhesion molecules:adipocyte-derived plasma protein adiponectin. Circulation 100:2473, 1999
  pubmed

• 32) Iwaki M et al:Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52:1655-1663, 2003
  pubmed

• 33) Hirose H et al:Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51:314-317, 2002
  pubmed

• 34) Tonelli J et al:Mechanisms of early insulin-sensitizing effects of thiazolidinediones in type 2 diabetes. Diabetes 53:1621-1629, 2004
  pubmed

• 35) Pajvani UB et al:Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162, 2004
  pubmed

• 36) Waki H et al:Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem 278:40352-40363, 2003
  pubmed

• 37) Pajvani UB et al:Structure-function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications fpr metabolic regulation and bioactivity. J Biol Chem 278:9073-9085, 2003
  pubmed

• 38) Tsuchida A et al:Peroxisome Proliferator-Activated Receptor (PPAR) α Activation Increases Adiponectin Receptors and Reduces Obesity-Related Inflammation in Adipose Tissue:Comparison of Activation of PPARα, PPARγ, and Their Combination. Diabetes 54:3358-3370, 2005

• 39) Kubota N et al:Pioglitazone Ameliorates Insulin Resistance and Diabetes by Both Adiponectin-dependent and -independent Pathways. J Biol Chem 281(13):8748-8755, 2006
  pubmed

• 40) Picard F et al:SRC-1 and TIF2 control energy balance between white and brown adipose tissues. Cell 111(7):931-941, 2002

• 41) Rocchi S et al:A unique PPARgamma ligand with potent insulin-sensitizing yet weak adipogenic activity. Mol Cell 8(4):737-747, 2001

• 42) Barbier O et al:Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Biol 22:717-726, 2002
  pubmed

• 43) Satoh H et al:Thiazolidinediones suppress endothelin-1 secretion from bovine vascular endothelial cells:a new possible role of PPARgamma on vascular endothelial function. Biochem Biophys Res Commun 254:757-763, 1999
  pubmed

• 44) Delerive P et al:Peroxisome proliferator-activated receptor activators inhibit thrombin-induced endothelin-1 production in human vascular endothelial cells by inhibiting the activator protein-1 signaling pathway. Circ Res 85:394-402, 1999
  pubmed

• 45) Murao K et al:Thiazolidinedione inhibits the production of monocyte chemoattractant protein-1 in cytokine-treated human vascular endothelial cells. FEBS Lett 454:27-30, 1999
  pubmed

• 46) Han KH, Quehenberger O:Ligands for peroxisome proliferator-activated receptor inhibit monocyte CCR2 expression stimulated by plasma lipoproteins. Trends Cardiovasc Med 10:209-216, 2000
  pubmed

• 47) Marx N et al:PPARalpha activators inhibit cytokine-induced vascular cell adhesion molecule-1 expression in human endothelial cells. Circulation 99:3125-3131, 1999
  pubmed

• 48) Jackson SM et al:Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler Thromb Vasc Biol 19:2094-2104, 1999

• 49) Pasceri V et al:Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-gamma activators. Circulation 101:235-238, 2000
  pubmed

• 50) Hanefeld M et al:One-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetes. Diabetes Care 27:141-147, 2004
  pubmed

• 51) Perez A et al:64th ADA Scientific Meeting, June, 2004, 0rlando

• 52) Iwaki M et al:Induction of adiponectin, a fat-derived antidiabetic and antiatherogenic factor, by nuclear receptors. Diabetes 52(7):1655-1663, 2003
  pubmed

• 53) Hirose H et al:Effects of pioglitazone on metabolic parameters, body fat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51(3):314-317, 2002
  pubmed

• 54) Hotta K et al:Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20(6):1595-1599, 2000
  pubmed

• 55) Kubota N et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277(29):25863-25866, 2002
  pubmed

• 56) Ouchi N et al:Association of hypoadiponectinemia with impaired vasoreactivity. Hypertension 42:231-234, 2003
  pubmed

• 57) Maeda N et al:Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8(7):731-737, 2002
  pubmed

• 58) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278(4):2461-2468, 2003
  pubmed

• 59) Law RE et al:Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia. J Clin Invest 98:1897-1905, 1996
  pubmed

• 60) Hsueh WA, Bruemmer D:Peroxisome proliferator-activated receptor gamma:implications for cardiovascular disease. Hypertension 43(2):297-305, 2004
  pubmed

• 61) Jiang C et al:PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 391:82-86, 1998
  pubmed

• 62) Ricote M et al:The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 391:79-82, 1998
  pubmed

• 63) Tontonoz P et al:PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252, 1998
  pubmed

• 64) Li AC et al:Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106:523-531, 2000
  pubmed

• 65) Chinetti G et al:PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001
  pubmed

• 66) Chawla A et al:A PPAR-gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171, 2001
  pubmed

• 67) Andrew C et al:Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARα, β/δ, and γ. J Clin Invest 114:1564-1576, 2004

• 68) Guan Y et al:Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861-866, 2005

P.40 掲載の参考文献

• 1) The DECODE study group on behalf of the European Diabetes Epidemiology Group:Glucose tolerance and motility:comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-619, 1999

• 2) Chiasson JL et al:STOP-NIDDM Trial Research Group:Acarbose for prevention of type 2 diabetes mellitus:the STOP-NIDDM randomized trial. Lancet 359:2072-2077, 2002

• 3) Hanefeld M et al:Acarbose reduces the risk for myocardial infarction in type 2 diabetic patients:meta-analysis of seven long-term studies. Eur Heart J 25:10-16, 2004
  pubmed

• 4) Diabetes Prevention Program Research Group:Effects of withdrawal from metformin on the development of diabetes in the diabetes prevention program. Diabetes Care 26:977-980, 2003

• 5) Zhou G et al:Role of AMP-activated protein kinase in mechanism of metformin action. J Clin Invest 108:1167-1174, 2001
  pubmed

• 6) Brown JB et al:Lactic acidosis rates in type 2 diabetes. Diabetes Care 21:1659-1663, 1998
  pubmed

• 7) Knowler WC et al:Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002

• 8) UK Prospective Diabetes Study (UKPDS) Group:Effect of intensive blood-glucose control with metformin on complication in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854-865, 1998

• 9) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial InmacroVascular Events):a randomized controlled trial. Lancet 366:1279-1289, 2005
  pubmed

2. 各種疾患におけるインスリン抵抗性

P.47 掲載の参考文献

• 1) Aguirre V et al:Phosphorylation of Ser307 in insulin receptor substrate-1 blocks interactions with the insulin receptor and inhibits insulin action. J Biol Chem 277:1531-1537, 2002
  pubmed

• 2) Hotamisligil GS et al:IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 271:665-668, 1996
  pubmed

• 3) Ueki K et hl:Central role of suppressors of cytokine signaling proteins in hepatic steatosis, insulin resistance, and the metabolic syndrome in the mouse. Proc Natl Acad Sci USA 101:10422-10427, 2004

• 4) Ueki K et al:Suppressor of cytokine signaling 1 (SOCS-1) and SOCS-3 cause insulin resistance through inhibition of tyrosine phosphorylation of insulin receptor substrate proteins by discrete mechanisms. Mol Cell Biol 24:5434-5446, 2004
  pubmed

• 5) Steppan CM et al:Activation of SOCS-3 by resistin. Mol Cell Biol 25:1569-1575, 2005
  pubmed

• 6) Rui L et al:SOCS-1 and SOCS-3 block insulin signaling by ubiquitin-mediated degradation of IRSI and IRS2. J Biol Chem 277:42394-42398, 2002

• 7) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 8) Yoon JC et al:Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 413:131-138, 2001
  pubmed

• 9) Koo SH et al:The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature 437:1109-1111, 2005
  pubmed

• 10) Shaw RJ et al:The kinase LKB1 mediates glucose homeostasis in liver and therapeutic effects of metformin. Science 310:1642-1646, 2005
  pubmed

• 11) Banerlee RR et al:Regulation of fasted blood glucose by resistin. Science 303:119-1198, 2004

• 12) Inoue H et al:Role of STAT-3 in regulation of hepatic gluconeogenic genes and carbohydrate metabolism in vivo. Nat Med 10:168-174, 2004
  pubmed

• 13) Inoue H et al:Role of hepatic STAT3 in brain-insulin action on hepatic glucose production. Cell Metab 3:267-275, 2006
  pubmed

• 14) Ceriello A, Motz E:Is oxidative stress the pathogenic mechanism underlying insulin resistance, diabetes, and cardiovascular disease? The common soil hypothesis revisited. Arterioscler Thromb Vasc Biol 24:816-823, 2004
  pubmed

• 15) Kamata H et al:Reactive Oxygen Species Promote TNFalpha-Induced Death and Sustained JNK Activation by Inhibiting MAP Kinase Phosphatases. Cell 120:649-661, 2005
  pubmed

• 16) Furukawa S et al:Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 114:1752-1761, 2004
  pubmed

• 17) Hirosumi J et al:Acentral role for JNK in obesity and insulin resistance. Nature 420:333-336, 2002

• 18) Ozcan U et al:Endoplasmic reticulum stress links obesity, insulin action, and type 2 diabetes. Science 306:457-461, 2004
  pubmed

• 19) Xu C et al:Endoplasmic reticulum stress:cell life and death decisions. J Clin Invest 115:2656-2664, 2005
  pubmed

• 20) Lowell BB, Shulman GI:Mitochondrial dysfunction and type 2 diabetes. Science 307:384-387, 2005
  pubmed

• 21) Mootha VK et al:Identification of a gene causing human cytochrome c oxidase deficiency by integrative genomics. Proc Natl Acad Sci USA 100:605-610, 2003
  pubmed

• 22) Patti ME et al:Coordinated reduction of genes of oxidative metabolism in humans with insulin resistance and diabetes:Potential role of PGC-1 and NRF1. Proc Natl Acad Sci USA 100:8466-8471, 2003

• 23) Hara K et al:A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to Type II diabetes. Diabetologia 45:740-743, 2002
  pubmed

• 24) Muller YL et al:A Gly482Ser missense mutation in the peroxisome proliferator-activated receptor gamma coactivator-1 is associated with altered lipid oxidation and early insulin secretion in Pima Indians. Diabetes 52:895-898, 2003
  pubmed

P.54 掲載の参考文献

• 1) 伊藤千賀子:OGTTの経年観察結果と2型糖尿病. 日本臨牀 60(suppl 8):111-118, 2002

• 2) DECODE Study Group:Glucose tolerance and mortality:comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 354:617-621, 1999

• 3) Tominaga M et al:Impaired glucose tolerance is a risk factor for cardiovascular disease, but not impaired fasting glucose:the Funagata Diabetes Study. Diabetes Care 22:920-924, 1999

• 4) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults:Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 285:2486-2497, 2001

• 5) Miyazaki T et al:Circulating malondialdehyde-modified LDL and atherogenic lipoprotein profiles measured by nuclear magnetic resonance spectroscopy in patients with coronary artery disease. Atherosclerosis, 179:139-145, 2005
  pubmed

• 6) 神出 計ほか:高血圧. 日本臨牀 62:1104-1107, 2004
  Medical*Online

• 7) Folli F et al:Angiotensin II inhibits insulin signaling in aortic smooth muscle cells at multiple levels. A potential role for serine phosphorylation in insulin/angiotensin II crosstalk. J Clin Invest 100:2158-2169, 1997

• 8) Maeda K et al:cDNA cloning and expression of a novel adipose specific collagen-like factor, apM1 (AdiPose Most abundant Gene transcript 1). Biochem Biophys Res Commun 221:286-289, 1996
  pubmed

• 9) Shimomura I et al:Enhanced expression of PAI-1 in visceral fat:possible contributor to vascular disease in obesity. Nat Med 2:800-803, 1996
  pubmed

• 10) 日本動脈硬化学会:動脈硬化性疾患治療ガイドライン2002年版

• 11) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
  pubmed

P.61 掲載の参考文献

• 1) Ginsberg HN et al:Regulation of plasma triglycerides in insulin resistance and diabetes. Arch Med Res 36:232-240, 2005
  pubmed

• 2) Merkel MJ et al:Lipoprotein lipase:genetics, lipid uptake, and regulation. J Lipid Res 43:1997-2006, 2002

• 3) Horowitz BS et al:Increased plasma and renal clearance of an exchangeable pool of apolipoprotein A-I in subjects with low levels of high density lipoprotein cholesterol. J Clin Invest 91:1743-1752, 1993
  pubmed

• 4) Abe H et al:Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1. J Clin Invest 101:1784-1788, 1998
  pubmed

• 5) Shibasaki M et al:Alterations of insulin sensitivity by the implantation of 3T3-L1 cells in nude mice. A role for TNF-alpha? Diabetologia 45:518-526, 2002
  pubmed

• 6) Yu YH et al:Adipocyte signaling and lipid homeostasis:sequelae of insulin-resistant adipose tissue. Circ Res 96:1042-1052, 2005
  pubmed

• 7) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 8) Hotamisligil GS et al:IRS-1-mediated inhibition of insulin receptor tyrosine kinase activity in TNF-alpha-and obesity-induced insulin resistance. Science 271:665-668, 1996
  pubmed

• 9) Ferre P:The biology of peroxisome proliferator-activated receptors:relationship with lipid metabolism and insulin sensitivity. Diabetes 53 Suppl 1:S43-50, 2004

• 10) Wolfrum C et al:Foxa2 regulates lipid metabolism and ketogenesis in the liver during fasting and in diabetes. Nature 432:1027-1032, 2004
  pubmed

3. チアゾリジン薬が期待される理由

P.67 掲載の参考文献

• 1) Miyazaki Y et al:Dose-response effect of pioglitazone on insulin sensitivity and insulin secretion in type 2 diabetes. Diabetes Care 25:517-523, 2002
  pubmed

• 2) Horton ES et al:Troglitazone in combination with sulfonylurea restores glycemic control in patients with type 2 diabetes. The Troglitazone Study Group. Diabetes Care 21:1462-1469, 1998

• 3) Fonseca V et al:Long-term effects of troglitazone:open-label extension studies in type 2 diabetic patients. Diabetes Care 23:354-359, 2000
  pubmed

• 4) Durbin RJ:Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 6:280-285, 2004
  pubmed

• 5) Knowler WC et al:Diabetes Prevention Program Research Group:Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150-1156, 2005

• 6) Azen SP et al:TRIPOD (TRoglitazone In the Prevention Of Diabetes):a randomized, placebo-controlled trial of troglitazone in women with prior gestational diabetes mellitus. Control Clin Trials 19:217-231, 1998

• 7) Dormandy JA et al;PROactive investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):arandomised controlled trial. Lancet 366(9493):1279-1289, 2005
  pubmed

• 8) Tan MH et al;GLAL Study Group:Comparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetes. Diabetes Care 28:544-550, 2005

• 9) St John Sutton M et al:A comparison of the effects of rosiglitazone and glyburide on cardiovascular function and glycemic control in patients with type 2 diabetes. Diabetes Care 25:2058-2064, 2002
  pubmed

• 10) Viberti G et al:A diabetes outcome progression trial (ADOPT):an international multicenter study of the comparative efficacy of rosiglitazone, glyburide, and metformin in recently diagnosed type 2 diabetes. Diabetes Care 25:1737-1743, 2002
  pubmed

• 11) Herman WH et al;RESULT Study Group:Reduction in use of healthcare services with combination sulfonylurea and rosiglitazone:findings from the Rosiglitazone Early vs SULfonylurea Titration (RESULT) study. Am J Manag Care 11:273-278, 2005

• 12) Kawasaki F et al:Structural and functional analysis of pancreatic islets preserved by pioglitazone in db/db mice. Am J Physiol Endocrinol Metab 288:E510-E518, 2005
  pubmed

• 13) Ceriello A et al:Comparison of effect of pioglitazone with metformin or sulfonylurea (monotherapy and combination therapy) on postload glycemia and composite insulin sensitivity index during an oral glucose tolerance test in patients with type 2 diabetes. Diabetes Care 28:266-272, 2005
  pubmed

P.74 掲載の参考文献

• 1) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
  pubmed

• 2) Kawamori R et al:Pioglitazone enhances splanchnic glucose uptake as well as peripheral glucose uptake in non-insulin-dependent diabetes mellitus. AD-4833 Clamp-OGL Study Group. Diabetes Res Clin Pract 41:35-43, 1998

• 3) Aronoff S et al:Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes:a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. Diabetes Care 23:1605-1611, 2000

• 4) Khan M et al:Effects of pioglitazone on the components of diabetic dyslipidaemia:results of double-blind, multicentre, randomised studies. Int J Clin Pract 58:907-912, 2004
  pubmed

• 5) Chawla A et al:A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7:161-171, 2001
  pubmed

• 6) Tontonoz P et al:PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252, 1998
  pubmed

• 7) Schoonjans K et al:PPARalpha and PPARgamma activators direct a distinct tissuespecific transcriptional response via a PPRE in the lipoprotein lipase gene. Embo J 15:5336-5348, 1996

• 8) Bogacka I et al:The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 27:1660-1667, 2004
  pubmed

• 9) van Wijk JP et al:Thiazolidinediones and blood lipids in type 2 diabetes. Arterioscler Thromb Vasc Biol 23:1744-1749, 2003
  pubmed

• 10) Chiquette E et al:A meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factors. Arch Intern Med 164:2097-2104, 2004
  pubmed

• 11) Lefebvre AM et al:Regulation of lipoprotein metabolism by thiazolidinediones occurs through a distinct but complementary mechanism relative to fibrates. Arterioscler Thromb Vasc Biol 17:1756-1764, 1997
  pubmed

P.81 掲載の参考文献

• 1) Yki-JarVinen H:Glucose toxicity. Endocr Rev 13:415-431, 1992
  pubmed

• 2) El-Assaad W et al:Saturated fatty acids synergize with elevated glucose to cause pancreatic β-cell death. Endocrinology 144:4154-4163, 2003

• 3) Patane G et al:Role of ATP production and uncoupling protein-2 in the insulin secretory defect induced by chronic exposure to high glucose or free fatty acids and effects of peroxisome proliferator-acitivated receptor-γ inhibition. Diabetes 51:2749-2756, 2002

• 4) Grankvist K et al:Cu, Zn-superoXide dismutase, Mn-superoxide dismutase, catalase and glutathione peroxidase in pancreatic islets and other tissues in the mouse. Biochem J 199:393-398, 1981

• 5) Dandona P et al:Oxidative damage to DNA in diabetes mellitus. Lancet 347:444-445, 1996
  pubmed

• 6) Ihara Y et al:Hyperglycemia causes oxidative stress in pancreatic β-cells of GK rats, a model of type 2 diabetes. Diabetes 48:927-932, 1999

• 7) Ishida H et al:Pioglitazone improves insulin secretory capacity and prevents the loss of β-cell mass in obese diabetic db/db mice:possible protection of βcells from oxidative stress. Metabolism 53:488-494, 2004

• 8) The Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150-1156, 2005

• 9) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
  pubmed

P.87 掲載の参考文献

• 1) Wild S et al:Global prevalence of diabetes:estimates for the year 2000 and projections for 2030. Diabetes Care 27:1047-1053, 2004
  pubmed

• 2) Zimmet P et al:Global and societal implications of the diabetes epidemic. Nature 414:782-787, 2001
  pubmed

• 3) http://www.mhlw.go.jp/shingi/2003/08/s0806-4.html

• 4) Buchanan TA et al:Preservation of pancreatic beta-cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk hispanic women. Diabetes 51:2796-2803, 2002
  pubmed

• 5) Durbin RJ:Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 6:280-285, 2004
  pubmed

• 6) Knowler WC et al:Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 346:393-403, 2002
  pubmed

• 7) Knowler WC et al:Diabetes Prevention Program Research Group. Prevention of type 2 diabetes with troglitazone in the Diabetes Prevention Program. Diabetes 54:1150-1156, 2005

P.94 掲載の参考文献

• 1) Sato K et al:Expression of peroxisome proliferator-activated receptor isoform proteins in the rat kidney. Hypertens Res 27:417-425, 2004
  pubmed

• 2) Guan Y et al:Peroxisome proliferator-activated receptors (PPARs):novel therapeutic targets in renal disease. Kidney Int 60:14-30, 2001
  pubmed

• 3) Bakris G et al:Rosiglitazone reduces urinary albumin excretion in type II diabetes. J Hum Hypertens 17:7-12, 2003
  pubmed

• 4) Sugawara A et al:Transcriptional suppression of type 1 angiotensin II receptor gene expression by peroxisome proliferator-activated receptor-gamma in vascular smooth muscle cells. Endocrinology 142:3125-3134, 2001
  pubmed

• 5) Pistrosch F et al:Rosiglitazone improves glomerular hyperfiltration, renal endothelial dysfunction, and microalbuminuria of incipient diabetic nephropathy in patients. Diabetes 54:2206-2211, 2005
  pubmed

• 6) Czoski-Murray C et al:Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes:a systematic review and economic evaluation. Health Technol Assess 8:iii, ix-x, 1-91, 2004

• 7) Chinetti G et al:PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7:53-58, 2001
  pubmed

• 8) Nakamura T et al:Effect of pioglitazone on carotid intima-media thickness and arterial stiffness in type 2 diabetic nephropathy patients. Metabolism 53:1382-1386, 2004
  pubmed

• 9) Isshiki K et al:Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats. Diabetes 49:1022-1032, 2000
  pubmed

• 10) Gumieniczek A:Effect of the new thiazolidinedione-pioglitazone on the development of oxidative stress in liver and kidney of diabetic rabbits. Life Sci 74:553-562, 2003
  pubmed

• 11) Nakamura T et al:Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 50:1193-1196, 2001
  pubmed

• 12) Sawano H et al:15-Deoxy-Delta12, 14-prostaglandin J2 inhibits IL-1beta-induced cyclooxygenase-2 expression in mesangial cells. Kidney Int 61:1957-1967, 2002
  pubmed

• 13) Guo B et al:Peroxisome proliferator-activated receptor-gamma ligands inhibit TGF-beta 1-induced fibronectin expression in glomerular mesangial cells. Diabetes 53:200-208, 2004
  pubmed

• 14) Agarwal R et al:A pilot randomized controlled trial of renal protection with pioglitazone in diabetic nephropathy. Kidney Int 68:285-292, 2005

• 15) Panchapakesan U et al:Drug Insight:thiazolidinediones and diabetic nephropathy-relevance to renoprotection. nature clinical practice nephrology 1:33-43, 2005

P.100 掲載の参考文献

• 1) Chen Z et al:Troglitazone inhibits atherosclerosis in apolipoprotein E-knockout mice:pleiotropic effects on CD36 expression and HDL. Arterioscler Thromb Vasc Biol 21(3):372-377, 2001
  pubmed

• 2) Li AC et al:Peroxisome proliferator-activated receptor gamma ligands inhibit development of atherosclerosis in LDL receptor-deficient mice. J Clin Invest 106(4):523-531, 2000
  pubmed

• 3) Collins AR et al:Troglitazone inhibits formation of early atherosclerotic lesions in diabetic and nondiabetic low density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 21(3):365-371, 2001
  pubmed

• 4) Chawla A et al:A PPAR gamma-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell 7(1):161-171, 2001
  pubmed

• 5) Babaev VR et al:Conditional knockout of macrophage PPARgamma increases atherosclerosis in C57BL/6 and low-density lipoprotein receptor-deficient mice. Arterioscler Thromb Vasc Biol 25(8):1647-1653, 2005
  pubmed

• 6) Chinetti G et al:PPAR-alpha and PPAR-gamma activators induce cholesterol removal from human macrophage foam cells through stimulation of the ABCA1 pathway. Nat Med 7(1):53-58, 2001
  pubmed

• 7) Li AC et al:Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest 114(11):1564-1576, 2004

• 8) Maeda N et al:PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50(9):2094-2099, 2001
  pubmed

• 9) Okamoto Y et al:Adiponectin reduces atherosclerosis in apolipoprotein E-deficient mice. Circulation 106(22):2767-2770, 2002
  pubmed

• 10) Kubota N et al:Disruption of adiponectin causes insulin resistance and neointimal formation. J Biol Chem 277(29):25863-25866, 2002
  pubmed

• 11) Matsuda M et al:Role of adiponectin in preventing vascular stenosis. The missing link of adipo-vascular axis. J Biol Chem 277(40):37487-37491, 2002

• 12) Tontonoz P et al:PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93(2):241-252, 1998
  pubmed

P.107 掲載の参考文献

• 1) メタボリックシンドローム診断基準検討委員会:メタボリックシンドロームの定義と診断基準. 日内誌 94. 794-809, 2005

• 2) Cosentino F et al:High glucose increases nitric oxide synthase expression and superoxide anion generation in human aortic endothelial cells. Circurlation 96:25-28, 1997
  pubmed

• 3) De Vriese AS et al:Endothelial dysfunction in diabetes. Br J Pharmacol 130:963-974, 2000
  pubmed

• 4) Shanmugan N et al:High glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 52:1256-1264, 2003

• 5) Carr ME:Diabetes Mellitus:A hypercoagulable state. J Diabetes Complications 15:44-54, 2001
  pubmed

• 6) Vinik AI et al:Platelet dysfunction in type 2 diabetes. Diabetes Care 24:1476-1485, 2001
  pubmed

• 7) Weyer C et al:Hypoadiponectinemia in obesity and type 2 diabetes:close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001
  pubmed

• 8) Ouchi N et al:Adipocyte-derived plasma protein, adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103:1057-1063, 2001

• 9) Olefsky JM:Treatment of insulin resistance with peroxisome proliferator-activated receptor γ agonists. J Clin Invest 106:467-472, 2000

• 10) 石田俊彦:インスリン抵抗性と肝細胞機能. 日本臨牀 58:348-356, 2000
  Medical*Online

• 11) Murase K et al:Pioglitazone time-dependently reduces tumor necrosis factor α level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 41:257-264, 1998

P.118 掲載の参考文献

• 1) Yuan M et al:Reversal of obesity- and diet-induced insulin resistance with salicylates or targeted disruption of Ikkβ. Science 293:1673-1677, 2001

• 2) Kamon J et al:A novel IKKβ inhibitor stimulates adiponectin levels and ameliorates obesity-linked insulin resistance. Biochem Biophys Res Commun 323:242-248, 2004

• 3) Hirosumi J et al:A central role for JNK in obesity and insulin resistance. Nature 420:333-336, 2002
  pubmed

• 4) Banerjee RR et al:Regulation of fasted blood glucose by resistin. Science 303:1195-1198, 2004
  pubmed

• 5) Kersten S et al:Roles of PPARs in health and disease. Nature 405:421-424, 2000
  pubmed

• 6) Yamauchi T et al:Increased insulin sensitivity despite lipodystrophy in Crebbp heterozygous mice. Nat Genet 30:221-226, 2002
  pubmed

• 7) Lin J et al:Defects in adaptive energy metabolism with CNS-linked hyperactivity in PGC-1alpha null mice. Cell 119(1):121-135, 2004
  pubmed

• 8) Kubota N et al:PPARγ mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609, 1999

• 9) Yamauchi T et al:The mechanisms by which both heterozygous peroxisome proliferator-activated receptorγ(PPARγ) deficiency and PPARγ agonist improve insulin resistance. J Biol Chem 276:41245-41254, 2001

• 10) Hara K et al:The Pro12Ala polymorphism in PPAR γ2 may confer resistance to type 2 diabetes. Biochem Biophys Res Commun 271:212-216, 2000

• 11) Yamauchi T et al:Inhibition of RXR and PPARγ ameliorates diet-induced obesity and type 2 diabetes. J Clin Invest 108:1001-1013, 2001

• 12) Yamauchi T et al:The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 13) Shimomura I et al:Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76, 1999
  pubmed

• 14) Mori Y et al:Genome-wide search for type 2 diabetes in Japanese affected sib-pairs confirms susceptibility genes on 3q, 15q, and 20q and identifies two new candidate Loci on 7p and 11p. Diabetes 51:1247-1255, 2002
  pubmed

• 15) Hara K et al:Genetic variation in the gene encoding adiponectin is associated with an increased risk of type 2 diabetes in the Japanese population. Diabetes 51:536-540, 2002
  pubmed

• 16) Yamauchi T et al:Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat Med 8:1288-1295, 2002
  pubmed

• 17) Yamauchi T et al:Globular adiponectin protected ob/ob mice from diabetes and ApoE-deficient mice from atherosclerosis. J Biol Chem 278:2461-2468, 2003
  pubmed

• 18) Yamauchi T et al:Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423:762-769, 2003
  pubmed

• 19) Tsuchida A et al:Insulin/Foxol pathway regulates expression levels of adiponectin receptors and adiponectin sensitivity. J Biol Chem 279:30817-30822, 2004

• 20) Tsuchida A et al:Peroxisome Proliferator-Activated Receptor (PPAR) α Activation Increases Adiponectin Receptors and Reduces Obesity-Related Inflammation in Adipose Tissue:Comparison of Activation of PPARα, PPARγ, and Their Combination. Diabetes 54:3358-3370, 2005

• 21) Narasimhan ML et al:Osmotin is a homolog of mammalian adiponectin and controls apoptosis in yeast through a homolog of mammalian adiponectin receptor. Mol Cell 17:171-180, 2005
  pubmed

• 22) Chawla A et al:A PPAR γ-LXR-ABCA1 pathway in macrophages is involved in cholesterol efflux and atherogenesis. Mol Cell7:161-171, 2001

• 23) Kubota N et al:Pioglitazone ameliorates insulin resistance and diabetes by both adiponectin-dependent and -independent pathways. J Biol Chem 281(13):8748-8755, 2006
  pubmed

• 24) Suzawa M et al:Cytokines suppress adipogenesis and PPAR-γ function through the TAK1/TAB1/NIK cascade. Nat Cell Biol 5:224-230, 2003

• 25) Pascual G et al:A SUMOylation-dependent pathway mediates transrepression of inflammatory response genes by PPAR-γ. Nature 437(7059):759-763, 2005

• 26) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
  pubmed

• 27) Schupp M et al:Angiotensin type 1 receptor blockers induce peroxisome proliferator-activated receptor-γ activity. Circulation 109:2054-2057, 2004

• 28) Benson SC et al:Identification of telmisartan as a unique angiotensin II receptor antagonist with selective PPAR γ-modulating activity. Hypertension 43:993-1002, 2004

• 29) Furuhashi M et al:Blockade of the renin-angiotensin system increases adiponectin concentrations in patients with essential hypertension. Hypertension 42:76-81, 2003
  pubmed

P.126 掲載の参考文献

• 1) Adler M, Schaffner F:Fatty liver hepatitis and cirrhosis in obese patients. Am J Med 67:811-816, 1979
  pubmed

• 2) Ludwig J et al:Nonalcoholic steatohepatitis:Mayo Clinic experience with an hitherto unnamed disease. Mayo Clin Proc 55:434-438, 1980

• 3) Angulo P:Nonalcoholic fatty liver disease. N Engl J Med 16:1221-1231, 2002
  pubmed

• 4) Clark JM et al:Nonalcoholic fatty liver disease. Gastroenterology 122:1649-1657, 2002
  pubmed

• 5) 石井裕正, 奥山哲二:非アルコール性脂肪性肝炎. 日本臨床 8:28-31, 1995

• 6) 石井裕正, 横山顕:アルコール性肝障害. 治療 78(臨時増刊号):636-638, 1995

• 7) Farrell GC:Non-alcoholic steatohepatitis:what is it, and why is it important in the Asia-Pacific region. J Gastroenterol Hepatol 18:124-138, 2003

• 8) Neuschwander-Tetri BA, Caldwell SH:Nonalcoholic steatohepatitis:summary of an AASLD single topic conference. Hepatology 37:1202-1219, 2003
  pubmed

• 9) Fatty Liver Disease:NASH and Related Disorders. Farrell GC et al eds. Malden, MA, Blackwell Publishing, 2005, pp1-319.

• 10) McCullough AJ:The epidemiology and risk factors of NASH. In:Fatty Liver Disease:NASH and Related Disorders. Farrell GC et al eds. Malden, MA, Blackwell Publishing, 2005, pp23-37.

• 11) George DK et al:Increased hepatic iron concentration in nonalcoholic steatohepatitis is associated with increased fibrosis. Gastroenterology 114:311-318, 1998
  pubmed

• 12) Bonkovsky HL et al:Non-alcoholic steatohepatitis and iron:increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis. J Hepatol 31:421-429, 1999
  pubmed

• 13) Norton R et al:Alcohol consumption and the risk of alcohol related cirrhosis in women. Br Med J (Clin Res Ed) 295:80-82, 1987
  pubmed

• 14) National Institutes of Health Consensus Development Conference Statement:Management of Hepatitis C:2002 -June 10-12, 2002. Hepatology 36(Suppl 1):S3-S21, 2002

• 15) Musso G et al:Dietary habits and their relations to insulin resistance and postprandial lipemia in nonalcoholic steatohepatitis. Hepatology 37:909-916, 2003
  pubmed

• 16) Bellentani S et al:Prevalence of and risk factors for hepatic steatosis in Northern Italy. Ann Intern Med 132:112-117, 2000
  pubmed

• 17) Bacon BR et al:Nonalcoholic steatohepatitis:an expanded clinical entity. Gastroenterology 107:1103-1109, 1994
  pubmed

• 18) Chitturi S et al:NASH and insulin resistance:insulin hypersecretion and specific association with the insulin resistance syndrome. Hepatology 35:373-379, 2002
  pubmed

• 19) Pagano G et al:Nonalcoholic steatohepatitis, insulin resistance, and metabolicsyndrome:further evidence for an etiologic association. Hepatology 35:367-372, 2002

• 20) Marchesini G et al:Nonalcoholic fatty liver, steatohepatitis, and the metabolic syndrome. Hepatology 37:917-923, 2003
  pubmed

• 21) Angelico F et al:Non-alcoholic fatty liver syndrome:a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol 18:1115-1117, 2003

• 22) Kral JG et al:Body fat topography as an independent predictor of fatty liver. Metabolism 42:548-551, 1993
  pubmed

• 23) Omagari K et al:Fatty liver in non-alcoholic non-overweight Japanese adults:Incidence and clinical characteristics. J Gastroenterol Hepato117:1089-1105, 2002

• 24) Hui J et al:Beyond insulin resistance in NASH:TNF-alpha or adiponectin? Hepatology 40:19-22, 2004
  pubmed

• 25) Lowell BB, Shulman GG:Mitochondrial dysfunction and type 2 diabetes. Science 307:384-387, 2005

• 26) Samuel VT et al:Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 279:32345-32353, 2004
  pubmed

• 27) Browning JD, Horton JD:Molecular mediators of hepatic steatosis and liver injury. J Clin Invest 114:147-152, 2004
  pubmed

• 28) Sanyal AJ et al:Nonalcoholic steatohepatitis:association of insulin resistance and mitochondrial abnormalities. Gastroenterology 120:1183-1192, 2001
  pubmed

• 29) Friedman J:Fat in all the wrong places. Nature 415:268-269, 2002
  pubmed

• 30) Saibara T et al:Bezafibrate for tamoxifen-induced non-alcoholic steatohepatitis. Lancet 353:1802, 1999
  pubmed

• 31) Duez H et al:Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice. J Biol Chem 277:48051-48057, 2002
  pubmed

• 32) Rubins HB et al:Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. N Engl J Med 341:410-418, 1999
  pubmed

• 33) Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes:the Diabetes Atherosclerosis Intervention Study, a randomised study. Lancet 357:905-910, 2001, [Erratum, Lancet 357:1890, 2001]

• 34) Nolan JJ et al:Improvement in glucose tolerance and insulin resistance in obese subjects treated With troglitazone. N Engl J Med 331:1188-1193, 1994
  pubmed

• 35) Suter SL et al:Metabolic effects of new oral hypoglycemic agent CS-045 in NIDDM subjects. Diabetes Care 15:193-203, 1992
  pubmed

• 36) Miyazaki Y et al:Eiifect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type 2 diabetic patients. Diabetologia 44:2210-2219, 2001
  pubmed

• 37) Bajaj M et al:Decreased plasma adiponectin concentrations are closely related to hepatic fat content and hepatic insulin resistance in pioglitazone-treated type 2 diabetic patients. J Clin Endocrinol Metab 89:200-206, 2004
  pubmed

• 38) Tack CJ et al:Insulin-induced vasodilatation and endothelial function in obesity/insulin resistance:effects of troglitazone. Diabetologia 41:569-576, 1998
  pubmed

• 39) Cavaghan MK et al:Treatment with the oral antidiabetic agent troglitazone improves beta cell responses to glucose in subjects with impaired glucose tolerance. J Clin Invest 100:530-537, 1997
  pubmed

• 40) Neuschwander-Tetri BA et al:Improved nonalcoholic steatohepatitis after 48 weeks of treatment with the PPAR-gamma ligand rosiglitazone. Hepatology 38:1008-1017, 2003
  pubmed

• 41) Promrat K et al:Apilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188-196, 2004

• 42) Tomita K et al:Pioglitazone prevents alcohol-induced fatty liver in rats through up-regulation of c-Met. Gastroenterology 126(3):873-885, 2004
  pubmed

• 43) Hasegawa T et al:Plasma transforming growth factor-betal level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis:a pilot study. Aliment Pharmacol Ther 15(10):1667-1672, 2001

• 44) Mayerson AB et al:The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002
  pubmed

• 45) Bajaj M et al:Pioglitazone reduces hepatic fat content and augments splanchnic glucose uptake in patients with type 2 diabetes. Diabetes 52:1364-1370, 2003
  pubmed

• 46) Kapoun AM et al:B-type natriuretic peptide exerts broad functional opposition to transforming growth factor-beta in primary human cardiac fibroblasts:fibrosis, myofibroblast conversion, proliferation, and inflammation. Circ Res 94(4):453-461, 2004
  pubmed

P.134 掲載の参考文献

• 1) Fonseca V et al:Long-term effects of troglitazone:open-label extension studies in type 2 diabetic patients. Diabetes Care 23:354-359, 2000
  pubmed

• 2) Sinha R et al:Assessment of skeletal muscle triglyceride content by 1H nuclear magnetic resonance spectroscopy in lean and obese adolescents:relationships to insulin sensitivity, total body fat, and central adiposity. Diabetes 51:1022-1027, 2002

• 3) Seppala-Lindroos A et al:Fat accumulation in the liver is associated with defects in insulin suppression of glucose production and serum free fatty acids independent of obesity in normal men. J Clin Endocrinol Metab 87:3023-3028, 2002

• 4) Virkamaki A et al:Intramyocellular lipid is associated with resistance to in vivo insulin actions on glucose uptake, antilipolysis, and early insulin signaling pathways in human skeletal muscle. Diabetes 50:2337-2343, 2001
  pubmed

• 5) Boden G:Role of fatty acids in the pathogenesis of insulin resistance and NIDDM. Diabetes 46:3-10, 1997
  pubmed

• 6) Kelley DE, Mandarino U:Fuel selection in human skeletal muscle in insulin resistance:areexamination (Review). Diabetes 49:677-683, 2000

• 7) McGarry JD:Banting Lecture 2001:Dysregulation of fatty acid metabolism in the etiology of type 2 diabetes. Diabetes 51:7-18, 2002
  pubmed

• 8) Ferranninin E et al:Effect of fatty acids on glucose production and utilization in man. J Clin Invest 72:1737-1747, 1983

• 9) Lang CH et al:Tumor necrosis factor impairs insulin action on peripheral glucose disposal and hepatic glucose output. Endocrinology 130:43-52, 1992
  pubmed

• 10) Rask-Madsen C et al:Tumor necrosis factor-α inhibits insulin's stimulating effect on glucose uptake and endothelium-dependent vasodilation in humans. Circulation 108:1815-1821, 2003

• 11) Hotamisligil GS et al:Adipose expression of tumor necrosis factor-α:direct role in obesity-linked insulin resistance. Science 259:87-91, 1993

• 12) Halaas JL et al:Weight-reducing effects of the plasma protein encoded by the obese gene. Science 269:543-546, 1995
  pubmed

• 13) Montague CT et al:Depot-related gene expression in human subcutaneous and omental adipocytes. Diabetes 47:1384-1391, 1998
  pubmed

• 14) Rossetti L et al:Short term effects of leptin on hepatic gluconeogenesis and in vivo insulin action. J Biol Chem 272:59-63, 1997

• 15) Shimomura I et al:Leptin reverses insulin resistance and diabetes mellitus in mice with congenital lipodystrophy. Nature 401:73-76, 1999
  pubmed

• 16) Yamauchi T et al:The fat derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat Med 7:941-946, 2001
  pubmed

• 17) Arita Y et al:Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257:79-83, 1999
  pubmed

• 18) Weyer C et al:Hypoadiponetinemia in obesity and type 2 diabetes:close association with insulin resistance and hyperinsulinemia. J Clin Endocrinol Metab 86:1930-1935, 2001
  pubmed

• 19) Persseghin G et al:Insulin resistance, intramyocellular lipid content, and plasma adiponectin in patients with diabetes. Am J Physiol 285:E1174-1181, 2003

• 20) Coombs TP et al:Endogenous glucose production is inhibited by the adipose-derived protein Acrp30. J Clin Invest 108:1875-1881, 2001

• 21) Okuno A et al:Troglitazone increase the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998
  pubmed

• 22) Auwerx J:PPARγ, the ultimate thrifty gene. Diabetologia 42:1033-1049, 1999

• 23) Adams M et al:Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation. J Clin Invest 100:3149-3153, 1997

• 24) Mori Y et al:Effects of troglitazone on body fat distribution in type 2 diabetic patients. Diabetic Care 22:908-912, 1999
  pubmed

• 25) Kelly IE et al:Effects of a thiazolidinedione compound on body fat and fat distribution of patients with type 2 diabetes. Diabetes Care 22:288-293, 1999
  pubmed

• 26) Miyazaki Y et al:Eiifect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 87:2784-2791, 2002
  pubmed

• 27) Miyazaki Y et al:Abdominal fat distribution and peripheral and hepatic insulin resistance in type 2 diabetes mellitus. Am J Physiol Endocrinol Metab 283:E1135-1143, 2002
  pubmed

• 28) Ye JM et al:Peroxisome proliferator-activated receptor (PPAR) -α activation lowers muscle lipids and improves insulin sensitivity in high fat-fed rats:comparison with PPAR-γactivation. Diabetes 50:411-417, 2001

• 29) Mayerson AB et al:The effects of rosiglitazone on insulin sensitivity, lipolysis, and hepatic and skeletal muscle triglyceride content in patients with type 2 diabetes. Diabetes 51:797-802, 2002
  pubmed

• 30) Bajaj M et al:Pioglitazone reduces hepatic fat content and augments splanchnic ghlcose uptake in patients with type 2 diabetes. Diabetes 52:1364-1370, 2003
  pubmed

• 31) Tiikkainen M et al:Effects of rosiglitazone and metformin on liver fat content, hepatic insulin resistance, insulin clearance, and gene expression in adipose tissue in patients with type 2 diabetes. Diabetes 53:2169-2176, 2004
  pubmed

• 32) Patel J et al:Rosiglitazone monotherapy improve glycaemic control in patients with type 2 diabetes:a twelve-week, randomized, placebo-controlled study. Diab Obes Metab 1:165-172, 1999

• 33) Miyazaki Y et al:Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in type 2 diabetic patients. Diabetologia 44:2210-2219, 2001
  pubmed

• 34) Maggs D G et al:Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus;arandomized, double-blind, placebo-controlled trial. Ann Intem Med 128:176-185, 1998

• 35) Fonseca VA et al and The Troglitazone Study Group:Troglitazone monotherapy improves glycemic control in patients with type 2 diabetes mellitus:a randomized, controlled study. J Clin Endocrinol Metab 83:3169-3176, 1998

• 36) Miyazaki Y et al:Improved glycemic control and enhanced insulin sensitivity in liver and muscle in type 2 diabetic subjects treated with pioglitazone. Diabetes Care24:710-719, 2001

• 37) Kageyama H et al:Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR-γ. Biochem BiophysRes Commun 305:22-27, 2003

• 38) Bogacka I et al:The effect of pioglitazone on peroxisome proliferator-activated receptor-gamma target genes related to lipid storage in vivo. Diabetes Care 27:1660-1667, 2004
  pubmed

• 39) Gasic S et al:Tumor necrosis factor alpha stimulates lipolysis in adipocytes by decreasing Gi protein concentrations. J Biol Chem 274:6770-6775, 1999
  pubmed

• 40) Murase K et al:Pioglitazone time-dependently reduces tumour necrosis factor-alpha level in muscle and improves metabolic abnormalities in Wistar fatty rats. Diabetologia 41:257-264, 1998
  pubmed

• 41) Osei K et al:Effects of rosglitazone on plasma adiponectin, insulin sensitivity, and insulin secretion in high-risk African Americans with impaired glucose tolerance test and type 2 diabetes. Metabolism 53:1552-1557, 2004
  pubmed

• 42) Miyazaki Y et al:Effect of pioglitazone on circulating adipocytokine levels and insulin sensitivity in type 2 diabetic patients. J Clin Endocrinol Metab 89:4312-4319, 2004
  pubmed

• 43) Considine RV, Caro JF:Leptin and the regulation of body weight. Int J Biochem Cell Biol 29:1255-1272, 1997
  pubmed

• 44) Satoh N et al:Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26:2493-2499, 2003
  pubmed

• 45) Kawamori R et al:PRACTICAL(Prospective ACTos practical experience) Study;Updated Ethcacy and Safety in 23,000 Japanese Type 2 Diabetes Patients. Diabetes 54(suppl 1):A112, 2005

• 46) Dormandy JA et al;PROactive investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
  pubmed

• 47) Bays H et al:Role of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type 2 diabetes mellitus:peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approach. J Clin Endocrinol Metab 89:463-478, 2004
  pubmed

4. チアゾリジンのわが国における臨床研究

P.141 掲載の参考文献

• 1) Rohde LE et al:Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. Am J Cardiol 84:1018-1022, 1999
  pubmed

• 2) Yla-Herttuala S et al:Evidence for the presence of oxidatively modified low density lipoprotein in atherosclerotic lesions of rabbit and man. J Clin Invest 84:1086-1095, 1989

• 3) Kashiwagi A et al:Endothelium-specific activation of NAD8P oxidase in aortas of exogenously hyperinsulinemic rats. Am J Physiol 277:E976-983, 1999
  pubmed

• 4) 芳野原ほか:ピオグリタゾンの2型糖尿病患者における尿中酸化ストレスマーカー及びhs-CRPに及ぼす効果について. Prog Med 23:1669-1673, 2003

• 5) 久保木幸司ほか:2型糖尿病者における酸化ストレス及び高感度CRP(hs-CRP)への血糖降下作用を介さないピオグリタゾン(Pio)の効果. 糖尿 47:S273, 2004

• 6) Yudkin JS et al:C-reactive protein in healthy subjects:associations with obesity, insulin resistance, and endothelial dysfunction:apotential role for cytokines originating from adipose tissue? Arterioscler Thromb Vasc Biol 19:972-978, 1999

• 7) Ishibashi M et al:Antiinflammatory and antiarteriosclerotic effects of pioglitazone. Hypertension 40:687-693, 2002
  pubmed

• 8) Satoh N et al:Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26:2493-2499, 2003
  pubmed

• 9) Igarashi M et al:Pioglitazone reduces smooth muscle cell density of rat carotid arterial intima induced by balloon catheterization. Horm Metab Res 29:444-449, 1997
  pubmed

• 10) Koshiyama H et al:Rapid communication:inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:3452-3456, 2001
  pubmed

• 11) Langenfeld MR et al:Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus:results from a controlled randomized study. Circulation 111:2525-2531, 2005
  pubmed

• 12) Pfutzner A et al:Improvement of cardiovascular risk markers by pioglitazone is independent from glycemic control:results from the pioneer study. J Am Coll Cardiol 45:1925-1931, 2005
  pubmed

• 13) Mehta JL et al:Pioglitazone inhibits LOX-1 expression in human coronary artery endothelial cells by reducing intracellular superoxide radical generation. Arterioscler Thromb Vasc Biol 23:2203-2208, 2003
  pubmed

• 14) Tsuji T et al:Pioglitazone improves left ventricular diastolic fUnction and decreases collagen accumulation in prediabetic stage of a type II diabetic rat. J Cardiovasc Pharmacol 38:868-874, 2001

• 15) Majithiya JB et al:Piog1itazone, a PPARgamma agonist, restores endothelial function in aorta of streptozotocin-induced diabetic rats. Cardiovasc Res 66:150-161, 2005
  pubmed

P.144 掲載の参考文献

• 1) Yudkin JS:Abnormalities of coagulation and fibrinolysis in insulin resistance. Diabetes Care 22:C25-C30, 1999
  pubmed

• 2) Thogersen AM et al:High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women. Circulation 98:2241-2247, 1998
  pubmed

• 3) Kohler HP et al:Plasminogen-activator inhibitor type 1 and coronary artery disease. N Engl J Med 342:1792-1801, 2000
  pubmed

• 4) 久保敬二:2型糖尿病患者の血液線溶因子と血管内皮機能マーカーに及ぼすピオグリタゾンの効果. 糖尿病 44:687-692, 2001

P.148 掲載の参考文献

• 1) Barbier O et al:Pleiotropic actions of peroxisome proliferator-activated receptors in lipid metabolism and atherosclerosis. Arterioscler Thromb Vasc Bio 122:717-726, 2002

• 2) Yki-Jarvinen H:Thiazolidinediones. N Engl J Med 351:1106-1118, 2004
  pubmed

• 3) Hirose H et al:Effect of pioglitaozne on metabolic parameters, body gat distribution, and serum adiponectin levels in Japanese male patients with type 2 diabetes. Metabolism 51:314-317, 2002

• 4) Koshiyama H et al:Inhibitory effect of pioglitaozne on carotid arterial wall thichness in type 2diabetes. J Clin Endocrinol Metab 86:3452-3456, 2001

• 5) Sidhu JS et al:Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Bio 124:930-934, 2004

• 6) Takagi T et al:Impact of troglitaozne on coronary stent implantation using small stents in patients with type 2 diabetes mellitus. Am J Cardiol 89:31-322, 2005

• 7) Satoh N et al:Antiatherogenic effect of pioglitazone in type 2 diabetic patients, irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26:2493-2499, 2003
  pubmed

• 8) Yki-Jarvinen H:The PROactive study:Some answers, many questions. Lancet 366:1241-1242, 2005
  pubmed

P.151 掲載の参考文献

• 1) Law RE et al:Troglitazone Inhibits Vascular Smooth Muscle Cell Growth and intimal Hyperplasia. J Clin Invest 98:1897-1905, 1996
  pubmed

• 2) Minamikawa J et al:Potent inhibitory effect of troglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 83:181-1820, 1998

• 3) Koshiyama H et al:Relationship between postprandial triglyceride level and intima-media thickness of carotid artery after troglitazone treatment in type 2 diabetes. In:Kita T, Yokode M (eds), Lipoprotein Metabolism and Atherogenesis, Springer, Tokyo, 2000, pp154-156

• 4) Nagy L et al:Oxidized LDL regulates macrophage gene expression through ligand activation of PPARgamma. Cell 93:229-240, 1998
  pubmed

• 5) Tontonoz P et al:PPARgamma promotes monocyte/macrophage differentiation and uptake of oxidized LDL. Cell 93:241-252, 1998
  pubmed

• 6) Spiegelman BM:PPARgamma in monocytes:less pain, any gain. Cell 93 (2):153-155, 1998
  pubmed

• 7) Moore KJ et al:The role of PPAR-gamma in macrophage differentiation and cholesterol uptake. Nat Med 7:41-47, 2001
  pubmed

• 8) Chawla A et al:PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med 7:48-52, 2001
  pubmed

• 9) Shimono D et al:Lack of effect of pioglitazone on postprandial triglyceride level in type 2 diabetes (letter). Diabetes Care 24:971, 2001

• 10) Koshiyama H et al:Inhibitory effect of pioglitazone on carotid arterial wall thickness in type 2 diabetes. J Clin Endocrinol Metab 86:3452-3456, 2001
  pubmed

• 11) Xiang AH et al:Effect of thiazolidinedione treatment on progression of subclinical atherosclerosis in premenopausal women at high risk for type 2 diabetes. J Clin Endocrinol Metab 90:1986-1991, 2005
  pubmed

• 12) Sidhu JS et al:Effect of rosiglitazone on common carotid intima-media thickness progression in coronary artery disease patients without diabetes mellitus. Arterioscler Thromb Vasc Biol 24:93-934, 2004

• 13) Langenfeld MR et al:Pioglitazone decreases carotid intima-media thickness independently of glycemic control in patients with type 2 diabetes mellitus:results from a controlled randomized study. Circulation 111:2525-2531, 2005
  pubmed

P.154 掲載の参考文献

• 1) Murakami T et al:Troglitazone restores endothelium-dependent vasomotion of resistance coronary artery. Circulation 98 (suppl. I):I-111, 1998

• 2) Murakami T et al:Effects of troglitazone on frequency of coronary vasospastic-induced angina pectoris in patients with diabetes mellitus. Am J Cardiol 84:92-94, 1999
  pubmed

• 3) Murakami T et al:Long-term treatment with thiazolidinedione improves vasomotion of resistance coronary arteries independent of improvements in clinical insulin resistance status. Circulation 110(suppl. III):III-180, 2004

P.159 掲載の参考文献

• 1) Campbell IW:The clinical significance of PPARgamma agonism. Curr Mol Med 5:349-363, 2005
  pubmed

• 2) Erdmann E:Microalbuminuria as a marker of cardiovascular risk in patients with type 2 diabetes. Int J Cardiol Jun 21 [Epub ahead of print], 2005

• 3) Matthews DR et al:Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes:a randomized, comparative study. Diabetes Metab Res Rev 21:167-174, 2005
  pubmed

• 4) Nakamura T et al:Effect of a specific Endothelin receptor A antagonist on mRNA levels for extracellular matrix components and growth factors I diabetic glomeruli. Diabetes 44:895-899, 1995
  pubmed

• 5) Nakamura T et al:Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary Endothelin-1 and albumin excretion in diabetes patients. J Diabetes its Complicate 14:250-254, 2000

• 6) Fujii M et al:Troglitazone ameliorates albuminuria in streptozotocin-induced diabetic rats. Metabolism 46:981-983, 1997
  pubmed

• 7) Yanagawa T et al:Effect of antidiabetic medications on microalbuminuria in patients with type 2 diabetes. Metabolism 53:353-357, 2004
  pubmed

• 8) Nakamura T et al:Urinary excretion of podocytes in patients with diabetic nephropathy. Nephrol Dial Transplant 15:1379-1383, 2000
  pubmed

• 9) Nakamura T et al:Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria. Metabolism 50:1193-1196, 2001
  pubmed

5. 糖尿病の大規模試験から

P.169 掲載の参考文献

• 1) Kawamori R et al:Interim analysis on PRACTICAL (Prospective Actos practical experiences) Study;Efficacy and safety in over 20,000 Japanese Type 2 Diabetes Patients. Presented at American Diabetes Association 64th Scientific Sessions. Diabetes 53 Suppl. A156, 2004

• 2) Kawamori R et al:PRACTICAL (Prospective Actos practical experiences) Study; Updated efficacy and safety in 23,000 Japanese Type 2 Diabetes Patients. Presented at American Diabetes Association 65th Scientific Sessions, 2005

• 3) Dormandy J et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
  pubmed

• 4) Guan Y et al:Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption. Nat Med 11 (8):861-866, 2005

P.177 掲載の参考文献

• 1) Durbin RJ:Thiazolidinedione therapy in the prevention/delay of type 2 diabetes in patients with impaired glucose tolerance and insulin resistance. Diabetes Obes Metab 6:280-285, 2004
  pubmed

• 2) Dormandy JA et al; PROactive investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366 (9493):1279-1289, 2005
  pubmed

• 3) Kawamori R et al:Hepatic safety profile and glycemic control of pioglitazone in more than 20,000 patients with type 2 diabetes mellitus:Postmarketing surveillance study in Japan. Diabetes Res Clin Pract (in press)

P.181 掲載の参考文献

• 1) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
  pubmed

• 2) Pasceri V et al:Modulation of vascular inflammation in vitro and in vivo by peroxisome proliferator-activated receptor-γ activators. Circulation 101:235-238, 2000

• 3) Tao L et al:Antioxidative, antinitrative, and vasculoprotective effects of a peroxisome proliferator-activated receptor-gamma agonist in hypercholesterolemia. Circulation 108:2805-2811, 2003
  pubmed

• 4) Takano H et al:Peroxisome proliferator-activated receptor activators inhibit lipopolysaccharide-induced tumor necrosis factor-α expression in neonatal rat cardiac myocytes. Circ Res 87:596-602, 2000

• 5) Asakawa M et al:Peroxisome proliferator-activated receptor gamma plays a critical role in inhibition of cardiac hypertrophy in vitro and in vivo. Circulation 105:1240-1246, 2002

• 6) Yue TL et al:In vivo myocardial protection from ischemia/reperfusion injury by the peroxisome proliferator-activated receptor-gamma agonist rosiglitazone. Circulation 104:2588-2594, 2001
  pubmed

• 7) Shiomi T et al:Pioglitazone, a peroxisome proliferator-activated receptor-gamma agonist, attenuates left ventricular remodeling and failure after experimental myocardial infarction. Circulation 106:3126-3132, 2002
  pubmed

• 8) Hasegawa H et al:Pioglitazone, a peroxisome proliferator-activated receptor gamma activator, ameliorates experimental autoimmune myocarditis by modulating Th1/Th2 balance. J Mol Cell Cardiol 38:257-265, 2005
  pubmed

• 9) Tang WH et al:Fluid retention after initiation of thiazolidinedione therapy in diabetic patients with established chronic heart failure. J Am Coll Cardiol 41:1394-1398, 2003
  pubmed

6. チアゾリジンの副作用とその対応 - 浮腫をめぐる新しい分子メカニズムを中心に

P.187 掲載の参考文献

• 1) Qin Y et al:Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes. Natute 436:356-362, 2005

• 2) Masuzaki H et al:Transgenic amplification of glucoconicoid action in adipose tissue causes high blood pressure in mice. J Clin Invest 112:83-90, 2003
  pubmed

• 3) Masuzaki H et al:Atransgenic model of visceral obesity and the metabolic syndrome. Science 294:2166-2170, 2001

• 4) Moller DE:New drug targets for type 2 diabetes and the metabolic syndrome. Nature 414:821-827, 2001
  pubmed

• 5) Dormandy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomized controlled trial. Lancet 366:1279-1289, 2005
  pubmed

• 6) Nesto RW et al:Thiazolidinedione use, fluid retention, and congestive heart failure:a consensus statement from the American Heart Association and American Diabetes Association. Circulation 108:2941-2948, 2003
  pubmed

• 7) Guan Y et al:Thiazolidinediones expand body fluid volume through PPAR γ stimulation of ENaC-mediated renal salt absorption. Nat Med 11:861-866, 2005

• 8) Zhang H et al:Collecting duct-specific deletion of peroxisome proliferator-activated receptor γ blocks thiazolidinedione-induced fluid retention. Proc Natl Acad Sci USA 102:9406-9411, 2005

• 9) Helledie T et al:The gene encoding the Acyl-CoA-binding protein is activated by peroxisome proliferator-activated receptor γ through an intronic response element functionally conserved between humans and rodents. J Biol Chem 277:26821-26830, 2002

7. チアゾリジン薬の使い方

P.193 掲載の参考文献

• 1) 心不全の観点からのアクトス適正使用のコンセンサスステートメント(平成18年5月策定)

• 2) Kubota N et al:PPAR gamma mediates high-fat diet-induced adipocyte hypertrophy and insulin resistance. Mol Cell 4:597-609, 1999
  pubmed

• 3) Dormandy JA et al:PROactive investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005
  pubmed

• 4) Hara K et al:Measurement of the high-molecular weight form of adiponectin in plasma is useful for the prediction of insulin resistance and metabolic syndrome. Diabetes Care 29:1357-1362, 2006
  pubmed

• 5) Pajvani UB et al:Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem 279:12152-12162, 2004
  pubmed

P.198 掲載の参考文献

• 1) メタボリックシンドローム診断基準検討委員会:日本内科学会雑誌:94:794-809, 2005

• 2) Okuno K et al:Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest 101:1354-1361, 1998

• 3) Maeda N et al:PPARgamma ligands increase expression and plasma concentrations of adiponectin, an adipose-derived protein. Diabetes 50:2094-2099, 2001
  pubmed

• 4) Satoh N et al:Antiatherogenic effect of pioglitazone in type 2 diabetic patients irrespective of the responsiveness to its antidiabetic effect. Diabetes Care 26:2493-2499, 2003
  pubmed

• 5) Gegick C et al:Comparison of effects of thiazolidinediones on cardiovascular risk factors:observations from a clinical practice. Endocr Pract 7:162-169, 2001
  pubmed

• 6) Dormandy J et al:Secondary prevention of macrovascular events in patients withtype 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):a randomised controlled trial. Lancet 366:1279-1289, 2005

• 7) Promat K et al:A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology 39:188-196, 2004

• 8) Nakamura T et al:Thiazolidinedione derivative improves fat distribution andmultiple risk factors in subjects with visceral fat accumulation-double-blind placebo-controlled trial. Diabetes Res Clin Pract 54:181-190, 2001

P.209 掲載の参考文献

• 1) Moses JW et al:Sirolimus-eluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 349:1315-1323, 2003

• 2) Falk E et al:Coronary plaque disruption. Circulation 92:657-671, 1995
  pubmed

• 3) Kimura T et al:Long-term clinical and angiographic follow-up after coronary stent placement in native coronary arteries. Circulation 105:2986-2991, 2002
  pubmed

• 4) The BARI Investigators:Infiuence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. The Bypass Angioplasty Revascularization Investigation(BARI). Circulation 96:1761-1769, 1997

• 5) Detre KM et al:The effect of previous coronary-artery bypass surgery on the prognosis of patients with diabetes who have acute myocardial infarction. Bypass Angioplasty Revascularization Investigation Investigators. N Engl J Med 342:989-997, 2000

• 6) Wang JC et al:Coronary artery distribution of acute myocardial infarction occlusions. Circulation 110:278-284, 2004
  pubmed

• 7) Brener SJ et al:Propensity analysis of long-term survival after surgical or percutaneous revascularization in patients with multivessel coronary artery disease and high-risk features. Circulation 109:2290-2295, 2004

• 8) Hannan EL et al:Long-term outcomes of coronary-artery bypass grafting versus stent implantation. N Engl J Med 352:2174-2183, 2005
  pubmed

• 9) UK Prospective Diabetes Study(UKPDS) Group:Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type2 diabetes (UKPDS33). Lancet 352(9131) :837-853, 1998

• 10) Hasadai D et al:Glycemic control and outcome of diabetic patients after successful percutaneous coronary revascularization. Am Heart J 141(1) :117-123, 2001

• 11) Katsuda Y et al:Glibenclamide, a selective inhibitor of ATP-sensitive K+Channels, attenustes metabolic coronary vasodilatation induced by pacing tachycardia in dogs. Circulation 92:511-517, 1995
  pubmed

• 12) Despres JP et al:Hyperinsulinemia as an independent risk factor for ischemic heart disease. N Engl J Med 334(15) :952-957, 1996
  pubmed

• 13) Weintraub WS et al:Outcome of coronary bypass surgery versus coronary angioplasty in diabetic patients with multivessel coronary artery disease. J Am Coll Cardiol 31:10-19, 1998
  pubmed

• 14) Mcguire DK et al:Association of diabetes mellitus and glycemic control strategies with clinical outcomes after acute coronary syndromes. Am Heart J 147(2) :246-252, 2004
  pubmed

• 15) Dormanndy JA et al:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study:a randomized controlled trial. Lancet 366(9493) :1279-1289, 2005

• 16) Marx N et al:Pioglitazone reduces neointima volume after coronary stent implantation:a randomized, placebo-controlled, double-blind trial in non-diabetic patients. Circulation 112(18) :2792-2798, 2005

8. PPAR標的薬の開発動向

P.215 掲載の参考文献

• 1) Laudet V et al:The Nuclear Receptor FactsBook, London, Academic Press, 2001, pp113-140, pp248-272

• 2) 村上浩二:PPAR標的薬の最近の動向. 分子糖尿病学の進歩2004 (矢崎義雄監修), 金原出版, 東京, 2004, pp123-129

• 3) Miller AR et al:Novel peroxisome proliferator-activated receptor ligands for Type 2 diabetes and the metabolic syndrome. Expert Opin Investig Drugs 12:1489-1500, 2003
  pubmed

• 4) 影近弘之ほか:PPARを標的とした創薬. 日本臨牀63(4) :549-555, 2005

• 5) Reginato MJ et al:A potent antidiabetic thiazolidinedione with unique peroxisome proliferator-activated receptorγ activating properties. J Biol Chem 273:32679-32684, 1998

• 6) Guerre-Millo M et al:Peroxisome proliferator-activated receptor alpha activators improve insulin sensitivity and reduce adiposity. J Biol Chem 275:16638-16642, 2000
  pubmed

• 7) Wang YX et al:Peroxisome proliferators-activated receptorδ activates fat metabolism to prevent obesity. Cell 113:159-170, 2003

• 8) Oliver WR et al:A selective peroxisome proliferator-activated receptorδ agonist promotes reverse cholesterol transport. Proc Natl Acad Sci USA 98:5306-5311, 2001

トピックス. 糖尿病合併症予防のための戦略研究 (J-DOIT3)

P.221 掲載の参考文献

• 1) http://www.pimrc.or.jp/

• 2) Yazaki Y, Kadowaki T:Combating diabetes and obesity in Japan. Nat Med 12:73-74, 2006
  pubmed

• 3) http://www.jdoit3.jp/

• 4) Gaede P et al:Multifactorial intervention and cardiovascular disease in patients with type2 diabetes. N Engl J Med 348(5):383-393, 2003

• 5) Dormandy JA et al;PROactive investigators:Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macro Vascular Events):a randomised controlled trial. Lancet 366 (9493):1279-1289, 2005

• 6) Colhoun HM et al:Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study(CARDS):multicentre randomised placebo-controlled trial. Lancet 364(9435):685-696, 2004
  pubmed